In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection

Cornea

Volumn 32, Issue 6, 2013, Pages 830-834

  Kowalski, Regis P ^a   Kowalski, Tyler A ^a   Shanks, Robert M Q ^a   Romanowski, Eric G ^a   Karenchak, Lisa M ^a   Mah, Francis S ^a  

^a University of Pittsburgh School of Medicine   (United States)

Author keywords

Antibiotics; Empiric topical therapy; Keratitis

Indexed keywords

CEFAZOLIN; CEFUROXIME; GENTAMICIN; MOXIFLOXACIN; TOBRAMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL KERATITIS; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; DRUG POTENCY; EPSILOMETER TEST; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORAXELLA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CEFAZOLIN; CEFUROXIME; CORNEAL ULCER; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; GENTAMICINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; QUINOLINES; TOBRAMYCIN;

EID: 84879159579     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318268d6f4     Document Type: Article

References (22)

1. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996;103:1854-1862.
2. O'Brien TP. Bacterial keratitis. In: Stephen Foster C, Azar DT, Dohlman CH, eds. Cephalosporins. "The Cornea-Smolin and Thoft's" Scientific Foundations & Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, pp 261-262.
3. O'Brien TP. Bacterial keratitis. In: Stephen Foster C, Azar DT, Dohlman CH, eds. Aminoglycosides. "The Cornea-Smolin and Thoft's" Scientific Foundations & Clinical Practice. 4th ed. 263-264.
4. Khokhar S, Sindhu N, Mirdha BR. Comparison of topical 0.3% ofloxacin to fortified tobramycin-cefazolin in the therapy of bacterial keratitis. Infection. 2000;28:149-152.
5. Kasetsuwan N, Tanthuvanit P, Reinprayoon U. The efficacy and safety of 0.5% levofloxacin versus fortified cefazolin and amikacin ophthalmic solution for the treatment of suspected and culture-proven cases of infectious bacterial keratitis: a comparative study. Asian Biomed. 2011;5:77-83.
6. Constantinou M, Daniell M, Snibson GR, et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology. 2007;114:1622-1629.
7. Parmar P, Salman A, Kalavathy CM, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol. 2006;141:282-286.
8. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.
9. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Vol 20. 4th ed. Villanova, PA: National Committee for Clinical Laboratory Standards; 2000. document M7-A5. No. 2.
10. Mather R, Karenchak LM, Romanowski EG, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
11. Clinical and Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Vol 29. 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. document M07-A8. No. 2.
12. Kowalski RP, Yates KA, Romanowski EG, et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987-1991.
13. Kowalski RP, Karenchak LM, Romanowski EG. Infectious disease: changing antibiotic susceptibility. Ophthalmol Clin North Am. 2003; 16:1-9.
14. Chambers HF, Sachdeva M. Binding of b-lactam antibiotics to penicillinbinding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990;161:1170-1176.
15. Hikida M, Mori M, Yoshida M, et al. Possible usefulness of cephem antibiotics with anti-staphylococcal activity for preventing the spread of methicillin-resistant Staphylococcus aureus. Jpn J Antibiot. 1993;46: 836-839.
16. Fallon MT, Shafer W, Jacob E. Use of cefazolin microspheres to treat localized methicillin-resistant Staphylococcus aureus infections in rats. J Surg Res. 1999;86:97-102.
17. Romanowski EG, Mah FS, Yates KA, et al. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. Am J Ophthalmol. 2005;139: 867-877.
18. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis. 2002;2:530-538.
19. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106:1313-1318.
20. Kowalski RP, Pandya AN, Karenchak LM, et al. An in vitro resistance study of levofloxacin, ciprofloxacin and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology. 2001;108:1826-1829.
21. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999;106:1319-1323.
22. Chaudhry NA, Flynn HW, Murray TG, et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128: 509-510.